Ultragenyx Pharmaceutical Inc.
Close on Oct 19, 2026
- Market cap
- $1.54B
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 3, 2026, after market close (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 4, 2026 | After market close | $214.00M | $-0.90 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 5, 2026 | After market close | $136.00M | $-1.84 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 12, 2026 | After market close | $207.00M | $-1.29 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 4, 2025 | After market close | $160.00M | $-1.81 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 5, 2025 | After market close | $166.00M | $-1.17 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 6, 2025 | After market close | $139.00M | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 13, 2025 | After market close | $165.00M | $-1.39 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 5, 2024 | After market close | $139.00M | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 1, 2024 | After market close | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 2, 2024 | After market close | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 15, 2024 | After market close | – | – | – |
Company guidance
Outlook given with results on Aug 4, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| total revenue | full year 2026 | $730.00M to $760.00M | Raised |
| Crysvita revenue | full year 2026 | $500.00M to $520.00M | Lowered |
| Dojolvi revenue | full year 2026 | $100.00M to $110.00M | Lowered |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Ultragenyx Pharmaceutical filed with the SEC
Ultragenyx Reports Second Quarter 2026 Financial Results and Corporate Update
Results of operations · EX-99.1 to Form 8-K
Ultragenyx Reports First Quarter 2026 Financial Results and Corporate Update
Results of operations · EX-99.1 to Form 8-K
Ultragenyx Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate Update
Results of operations · Exit or restructuring costs · EX-99.1 to Form 8-K
Ultragenyx Provides Financial and Business Updates at J.P. Morgan Annual Healthcare Conference
Results of operations · EX-99.1 to Form 8-K
Ultragenyx Reports Third Quarter 2025 Financial Results and Corporate Update
Material agreement · Results of operations · EX-99.1 to Form 8-K
Ultragenyx Reports Second Quarter 2025 Financial Results and Corporate Update
Results of operations · EX-99.1 to Form 8-K
Ultragenyx Reports First Quarter 2025 Financial Results and Corporate Update
Results of operations · EX-99.1 to Form 8-K
Ultragenyx Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Update
Results of operations · EX-99.1 to Form 8-K
Ult ragenyx Reports Preliminary 2024 Revenue, Financial Guidance for 2025,
Results of operations · EX-99.1 to Form 8-K
Ultragenyx Reports Third Quarter 2024 Financial Results and Corporate Update
Results of operations · EX-99.1 to Form 8-K
Ultragenyx Reports Second Quarter 2024 Financial Results and Corporate Update
Results of operations · EX-99.1 to Form 8-K
Ultragenyx Reports First Quarter 2024 Financial Results and Corporate Update
Results of operations · EX-99.1 to Form 8-K
Ultragenyx Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Update
Results of operations · EX-99.1 to Form 8-K
Ultragenyx Reports Preliminary 2023 Revenue; Guidance for 2024 Revenue and Cash Usage;
Results of operations · EX-99.1 to Form 8-K
Ultragenyx Reports Third Quarter 2023 Financial Results and Corporate Update
Results of operations · EX-99.1 to Form 8-K
Ultragenyx and Mereo BioPharma Announce Interim Phase 2 Data from Phase 2/3 Orbit Study
Results of operations · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Ultragenyx Announces Program and Pipeline Updates at Analyst Day Including Interim Data from Ongoing
Results of operations · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
GTX-102 for Angelman Syndrome Phase
Results of operations · Regulation FD disclosure · Other events · EX-99.3 to Form 8-K
Ultragenyx Reports Second Quarter 2023 Financial Results and Corporate Update
Results of operations · EX-99.1 to Form 8-K
Ultragenyx Appoints Howard Horn as Chief Financial Officer and Executive Vice President, Corporate Strategy
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Ultragenyx Announces First Patients Dosed in Phase 3 Program Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI)
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Ultragenyx and Mereo BioPharma Announce Positive Data from the Ongoing Phase 2/3 Orbit Study of Setrusumab (UX143) in Osteogenesis Imperfecta (OI)
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Ultragenyx Reports First Quarter 2023 Financial Results and Corporate Update
Results of operations · EX-99 to Form 8-K
Ultragenyx Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Update
Results of operations · EX-99 to Form 8-K
Ultragenyx Reports Preliminary 2022 Revenue; Guidance for 2023 Revenue and Cash Usage; Pipeline Updates and 2023 Milestones
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Ultragenyx Reports Third Quarter 2022 Financial Results and Corporate Update
Results of operations · EX-99.1 to Form 8-K
Ultragenyx Reports Second Quarter 2022 Financial Results and Corporate Update
Results of operations · EX-99.1 to Form 8-K
Ultragenyx and GeneTx Provide Program Update on GTX-102 for Angelman Syndrome Including Promising Interim Data from Phase 1/2 Study
Material agreement · Acquisition or disposition completed · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Ultragenyx Announces Sale of a Portion of Future North American Royalties on Crysvita® (burosumab) for $500 Million to OMERS Capital Markets
Material agreement · Other events · EX-99.1 to Form 8-K
Ultragenyx Acquires Global Rights to AAV Gene Therapy ABO-102 for Sanfilippo Syndrome Type A (MPS IIIA) from Abeona Therapeutics
Other events · EX-99.1 to Form 8-K
Ultragenyx Reports First Quarter 2022 Financial Results and Corporate Update
Results of operations · EX-99.1 to Form 8-K
Ultragenyx Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Update
Results of operations · EX-99.1 to Form 8-K
ULTRAGENYX REPORTS PRELIMINARY 2021 REVENUE AND 2022 REVENUE GUIDANCE FOR CRYSVITA ® IN ULTRAGENYX TERRITORIES* AND DOJOLVI ® GLOBALLY; PROVIDES PIPELINE UPDATES AND 2022 MILESTONES
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Regeneron and Ultragenyx Collaborate to Commercialize Evkeeza ® (evinacumab) Outside the United States
Other events · EX-99.1 to Form 8-K
Ultragenyx Reports Third Quarter 2021 Financial Results and Corporate Update
Results of operations · EX-99.1 to Form 8-K
GeneTx and Ultragenyx Announce First Patient Dosed in Canada in Phase 1/2 Clinical Trial of GTX-102 in Patients with Angelman Syndrome
Other events · EX-99.1 to Form 8-K